# ASX Announcement
# 13 May 2024 (Melbourne, Australia)
# Optiscan Imaging Ltd (ASX:OIL)

## Optiscan Webinar Following Mayo Clinic Agreement

**Optiscan Imaging Limited** (**ASX:OIL**) ('**Optiscan**' or '**The Company**') is pleased to announce that Chief Executive Officer and Managing Director, Dr Camile Farah will host an investor webinar presentation following the announcement that the Company has entered into a collaboration through a know-how agreement with Mayo Clinic to develop a digital confocal laser endomicroscopic imaging system for use in robotic surgery. The presentation will provide an update on the current operational focus, outlook for the Company, and impact of the Mayo Clinic announcement.

| | |
|---|---|
| **Date** | Thursday 16 May 2024 |
| **Time** | 11:00 AEST |
| **Format** | Zoom |
| **Register** | The event is free, and investors can register online here**:** https://us02web.zoom.us/webinar/register/WN_uB0zx1qVQwWN7iaoIOQojA |

Shareholder questions can be submitted on the day through Zoom or emailed to Russell Katz (russell@thecapitalnetwork.com.au) ahead of the webinar.

A recorded copy of the webinar will be made available following the event on Optiscan's YouTube channel: https://www.youtube.com/@optiscanimagingltd4431

– ends –

This announcement has been authorised for release by the Board of Optiscan.

### For further information, please contact:


Shareholder & General Enquiries
Optiscan Imaging Ltd
Dr Camile Farah
M: +61 3 9538 3333
E: ceo@optiscan.com

Media & Investor Enquiries
The Capital Network
Russell Katz
M: +61 2 8999 3699
E: russell@thecapitalnetwork.com.au

## About Optiscan

Optiscan Imaging Ltd (ASX:OIL) is a global leader in the development, manufacturing, and commercialisation of confocal endomicroscopic imaging technologies for medical, translational and pre-clinical applications. Our technology enables real-time, non-destructive, 3D, in-vivo digital imaging at the single-cell level.

We are driven by developing technology and its use to give healthcare providers and researchers the highest quality real-time microscopic imaging tools to enable the early detection and management of disease, improve patient outcomes, and reduce the high cost of curative medicine and associated procedures.

Our patent-protected proprietary technology, using specially miniaturised componentry, has created a pen-sized digital microscope, which can be used on any tissue it contacts to produce high resolution digital pathology images for cancer diagnosis and surgical margin detection in real-time. The aim of our technology development is for earlier diagnosis and subsequent treatment of cancerous tumours with expected associated improved patient outcomes.

To learn more about Optiscan, visit www.optiscan.com or follow us on LinkedIn, X or Instagram.

## Disclaimer

*All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of Optiscan or any of the other parties referred to herein, are forward-looking statements. Forward-looking statements can be identified by words such as 'anticipate", "believe", "could", "estimate", "expect", "future", "intend", "may", "opportunity", "plan", "potential", "project", "seek", "will" and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of Optiscan that could cause actual results to differ from the results expressed or anticipated in these statements.*